Sanofi: (NYSE: SNY)
$53.40
-1.16 (-2.13%)
Volume 512,646
Jun 19 04:02 PM ET
Zacks Rank: 3-Hold 
| #3 |
Overview Quote
Stock Activity
| Day Low - High | 53.30 - 54.67 |
| 52wk Low - High | 35.22 - 55.94 |
| Previous Close | 54.56 |
| Avg. Volume | 1,035,275 |
| Industry | LARGE CAP PHARMA |
| Market Cap | 146.32 B |
| Div - Yield | 1.25 - 2.30 |
| Beta | 0.91 |
| P/E (F1) | 14.56 |
| Current Year Est. | 3.75 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
 3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
175 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| P/E (F1) | 14.56 |
| PEG Ratio | 2.43 |
| Current Year Est. | 3.75 |
| Current Quarter Estimate | 0.93 |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 07-25-2013 |
| EPS Last Year | 3.58 |
| Expected Earnings Growth | 6.00% |
Company Description
Sanofi-Aventis is a global pharmaceutical company that contributes to enhance life by providing medicines, vaccines, and integrated healthcare solutions adapted to local needs and means primarily in Europe and the United States. The company is engaged in the research, development, manufacture and marketing of healthcare products. Its strategy is built around three priorities to reach its goals and ensure sustainable growth. The priorities are: increasing innovation in Research and Development, adapting Group structures to future challenges and seizing external growth opportunities. Sanofi-Aventis specializes in six therapeutic areas: thrombosis, cardiovascular, metabolic disorders, oncology, central nervous system (CNS) and internal medicine. The Company offers vaccines in five areas: pediatric combination vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi-Aventis is headquartered in Paris, France.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | 0.93 | 1.09 | 3.75 | 4.30 |
| Number of Estimates | 2 | 2 | 5 | 5 |
| Low Estimate | 0.89 | 1.08 | 3.65 | 4.18 |
| High Estimate | 0.96 | 1.10 | 3.90 | NA |
| Year Ago EPS | 0.90 | 1.10 | 4.13 | 3.75 |
| EPS Growth | 2.78% | -0.91% | -9.25% | 14.67% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| SANOFI-AVENTIS | SNY | 54.56 | |
|
| NOVO-NORDISK AS | NVO | 161.87 | |
|
| ABBOTT LABS | ABT | 37.51 | |
|
| ABBVIE INC | ABBV | 43.54 | |
|
| ALLERGAN INC | AGN | 101.49 | |
|
| ASTRAZENECA PLC | AZN | 50.98 | |
|
| BRISTOL-MYERS | BMY | 46.85 | |
|
| GLAXOSMITHKLINE | GSK | 52.47 | |
|
| JOHNSON & JOHNS | JNJ | 86.36 | |
|
| LILLY ELI & CO | LLY | 52.35 | |
|
Sector:Medical>> Industry:LARGE CAP PHARMA
COMPARE TICKER vs. Its Peers
Zacks Commentary
Good News for InterMune
Jun 17, 2013
Sanofi's Fluzone Quadrivalent Gets FDA Nod
Jun 13, 2013
CHMP Positive on Sanofi's Lantus
Jun 11, 2013
Glaxo Reports Disappointing Tykerb Data
Jun 10, 2013
FDA Panel Positive on GSK's Avandia
Jun 07, 2013
Astellas, Tecnofarma in Distribution Deal
Jun 06, 2013
Encouraging data from Bristol-Myers
Jun 05, 2013
Pipeline Setbacks at Sanofi
Jun 04, 2013
Financials
| EPS TTM | 3.58 |
| Sales | 47,349 |
| Net Income | 5,325 |
| Price/Earnings | 15.24 |
| Price/Book | 1.96 |
| Price/Cash Flow | 8.39 |
| Price/Sales | 3.28 |
News
Pharma Rx? $105B Saved If Patients Took Meds - YCharts
Jun 19, 2013
Short-term Underperformance Detected in Shares of Vivus in the Pharmaceuticals Industry (VVUS, ENDP, SNY, VPHM, GSK) - Financial News Network Online - News Corner
Jun 19, 2013
The Diabetes Drug War - TheMotleyFool
Jun 19, 2013
Is a Type 1 Diabetes Cure Right Around the Corner? - TheMotleyFool
Jun 18, 2013
Canadians Look to Their Employers to Help Navigate the Public-Private Healthcare Maze - Cnw Group
Jun 17, 2013
Leading Experts in Parenting, Education and Medicine Partner to Launch Head Lice Awareness Initiative - Pr Newswire
Jun 17, 2013
Pharma Stocks: Court Ruling`s Real Meaning - YCharts
Jun 17, 2013
Sanofi (SNY) Showing Support Near $53.14 With 2.34% Dividend Yield - Freshbrewedmedia
Jun 17, 2013
Broker Recommendations
| Current ABR | 1.25 |
| ABR (Last Week) | 1.25 |
| # of recs in ABR | 8 |
| Average Target Price | 54.93 |
| Industry Rank by ABR | 175 out of 265 |
| Rank in Industry | 2 out of 15 |
